BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Sep 20, 2010
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Fidaxomicin: Additional Phase III data

Pooled data from a pair of double-blind Phase III trials in 1,164 patients showed that in patients with a recurrent episode of CDI within 3 months of entering the trials (n=128), fidaxomicin significantly reduced the proportion of patients who experienced another recurrence vs. Vancocin vancomycin (19.7% vs. 35.5%, p=0.045). In 336 evaluable patients...

Read the full 253 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >